Aquestive Total Current Liabilities from 2010 to 2025
| AQST Stock | USD 3.21 0.09 2.88% |
Total Current Liabilities | First Reported 2007-03-31 | Previous Quarter 15.2 M | Current Value 18.9 M | Quarterly Volatility 9.1 M |
Check Aquestive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aquestive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 10.3 M, Selling General Administrative of 44.5 M or Total Revenue of 49.6 M, as well as many indicators such as Price To Sales Ratio of 3.99, Dividend Yield of 0.0 or Days Sales Outstanding of 63.82. Aquestive financial statements analysis is a perfect complement when working with Aquestive Therapeutics Valuation or Volatility modules.
Aquestive | Total Current Liabilities |
Latest Aquestive Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Aquestive Therapeutics over the last few years. Total Current Liabilities is an item on Aquestive Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aquestive Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Aquestive Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aquestive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Aquestive Total Current Liabilities Regression Statistics
| Arithmetic Mean | 17,090,112 | |
| Geometric Mean | 14,361,848 | |
| Coefficient Of Variation | 54.35 | |
| Mean Deviation | 6,852,362 | |
| Median | 18,308,000 | |
| Standard Deviation | 9,287,882 | |
| Sample Variance | 86.3T | |
| Range | 38M | |
| R-Value | 0.67 | |
| Mean Square Error | 50.5T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | 1,314,034 | |
| Total Sum of Squares | 1294T |
Aquestive Total Current Liabilities History
About Aquestive Therapeutics Financial Statements
Aquestive Therapeutics shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Aquestive Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aquestive Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aquestive Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 18.9 M | 20.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.